Liu Aimei, Liu Sang, Lv Kangyan, Zhu Qingdong, Wen Jun, Li Jianpeng, Liang Chengyuan, Huang Xuegang, Gong Chunming, Sun Qingfeng, Gu Hongcang
Department of Tuberculosis, Guangxi Zhuang Autonomous Region Chest Hospital, Liuzhou, Guangxi, China.
Department of Tuberculosis, The Fourth People's Hospital of Nanning, Nanning, Guangxi, China.
Front Microbiol. 2024 Mar 1;15:1349715. doi: 10.3389/fmicb.2024.1349715. eCollection 2024.
Resistance to anti-tuberculous drugs is a major challenge in the treatment of tuberculosis (TB). We aimed to evaluate the clinical availability of nanopore-based targeted next-generation sequencing (NanoTNGS) for the diagnosis of drug-resistant tuberculosis (DR-TB).
This study enrolled 253 patients with suspected DR-TB from six hospitals. The diagnostic efficacy of NanoTNGS for detecting and its susceptibility or resistance to first- and second-line anti-tuberculosis drugs was assessed by comparing conventional phenotypic drug susceptibility testing (pDST) and Xpert MTB/RIF assays. NanoTNGS can be performed within 12 hours from DNA extraction to the result delivery.
NanoTNGS showed a remarkable concordance rate of 99.44% (179/180) with the culture assay for identifying the complex. The sensitivity of NanoTNGS for detecting drug resistance was 93.53% for rifampicin, 89.72% for isoniazid, 85.45% for ethambutol, 74.00% for streptomycin, and 88.89% for fluoroquinolones. Specificities ranged from 83.33% to 100% for all drugs tested. Sensitivity for rifampicin-resistant tuberculosis using NanoTNGS increased by 9.73% compared to Xpert MTB/RIF. The most common mutations were S531L (codon in E. coli) in the gene, S315T in the gene, and M306V in the gene, conferring resistance to rifampicin, isoniazid, and ethambutol, respectively. In addition, mutations in the pncA gene, potentially contributing to pyrazinamide resistance, were detected in 32 patients. Other prevalent variants, including D94G in the gene and K43R in the gene, conferred resistance to fluoroquinolones and streptomycin, respectively. Furthermore, the R94Q mutation was detected in one sample, indicating potential resistance to bedaquiline.
NanoTNGS rapidly and accurately identifies resistance or susceptibility to anti-TB drugs, outperforming traditional methods. Clinical implementation of the technique can recognize DR-TB in time and provide guidance for choosing appropriate antituberculosis agents.
耐抗结核药物是结核病治疗中的一项重大挑战。我们旨在评估基于纳米孔的靶向新一代测序技术(NanoTNGS)在耐多药结核病(DR-TB)诊断中的临床实用性。
本研究纳入了来自六家医院的253例疑似DR-TB患者。通过比较传统的表型药物敏感性试验(pDST)和Xpert MTB/RIF检测,评估了NanoTNGS检测结核分枝杆菌复合群及其对一线和二线抗结核药物的敏感性或耐药性的诊断效能。NanoTNGS从DNA提取到结果报告可在12小时内完成。
NanoTNGS在鉴定结核分枝杆菌复合群方面与培养检测显示出99.44%(179/180)的显著一致性率。NanoTNGS检测耐药性的敏感性分别为:利福平93.53%、异烟肼89.72%、乙胺丁醇85.45%、链霉素74.00%、氟喹诺酮类88.89%。所有检测药物的特异性范围为83.33%至100%。与Xpert MTB/RIF相比,使用NanoTNGS检测利福平耐药结核病的敏感性提高了9.73%。最常见的突变是rpoB基因中的S531L(大肠杆菌密码子)、katG基因中的S315T和embB基因中的M306V,分别赋予对利福平、异烟肼和乙胺丁醇的耐药性。此外,在32例患者中检测到可能导致吡嗪酰胺耐药的pncA基因突变。其他常见变异,包括gyrA基因中的D94G和rrs基因中的K43R,分别赋予对氟喹诺酮类和链霉素的耐药性。此外,在一个样本中检测到rplB基因的R94Q突变,表明对贝达喹啉可能耐药。
NanoTNGS能快速准确地鉴定对抗结核药物的耐药性或敏感性,优于传统方法。该技术的临床应用可及时识别DR-TB,并为选择合适的抗结核药物提供指导。